CN104531590A - Fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll - Google Patents
Fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll Download PDFInfo
- Publication number
- CN104531590A CN104531590A CN201510018144.4A CN201510018144A CN104531590A CN 104531590 A CN104531590 A CN 104531590A CN 201510018144 A CN201510018144 A CN 201510018144A CN 104531590 A CN104531590 A CN 104531590A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- bacterial strain
- bifidobacterium animalis
- cholesterol
- bzll
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186000 Bifidobacterium Species 0.000 title claims abstract description 32
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 title abstract description 10
- 239000001301 oxygen Substances 0.000 title abstract description 10
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 114
- 230000001580 bacterial effect Effects 0.000 claims description 74
- 235000012000 cholesterol Nutrition 0.000 claims description 52
- 241000894006 Bacteria Species 0.000 claims description 49
- 230000003247 decreasing effect Effects 0.000 claims description 27
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 24
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 21
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 21
- 238000002474 experimental method Methods 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 15
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 13
- 241000186361 Actinobacteria <class> Species 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 8
- 238000003304 gavage Methods 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 241001156739 Actinobacteria <phylum> Species 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- 230000000877 morphologic effect Effects 0.000 claims description 6
- 229960004261 cefotaxime Drugs 0.000 claims description 5
- 229960003405 ciprofloxacin Drugs 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 229960000564 nitrofurantoin Drugs 0.000 claims description 5
- 229960002292 piperacillin Drugs 0.000 claims description 5
- 229960001225 rifampicin Drugs 0.000 claims description 5
- 229960003165 vancomycin Drugs 0.000 claims description 5
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- 108010059993 Vancomycin Proteins 0.000 claims description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 4
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 4
- 229960004682 cefoperazone Drugs 0.000 claims description 4
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 4
- 229960003324 clavulanic acid Drugs 0.000 claims description 4
- 229940047766 co-trimoxazole Drugs 0.000 claims description 4
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 4
- 229960001699 ofloxacin Drugs 0.000 claims description 4
- 229940056360 penicillin g Drugs 0.000 claims description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 150000004684 trihydrates Chemical class 0.000 claims description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 4
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 3
- MQTOSJVFKKJCRP-HHZDEWPHSA-N Azythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@H]([C@@]([C@H](O)[C@H](C)N(C)C[C@@H](C)C[C@](C)(O)[C@@H](O[C@@H]2[C@H]([C@@H](C[C@H](C)O2)N(C)C)O)[C@@H]1C)(C)O)CC)[C@@H]1C[C@](C)(OC)[C@H](O)[C@@H](C)O1 MQTOSJVFKKJCRP-HHZDEWPHSA-N 0.000 claims description 3
- 241001430332 Bifidobacteriaceae Species 0.000 claims description 3
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 claims description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 3
- 231100000403 acute toxicity Toxicity 0.000 claims description 3
- 230000007059 acute toxicity Effects 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 150000007660 quinolones Chemical class 0.000 claims description 3
- 230000009897 systematic effect Effects 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 238000012790 confirmation Methods 0.000 claims description 2
- 150000002596 lactones Chemical class 0.000 claims description 2
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 abstract description 8
- 239000002253 acid Substances 0.000 abstract description 7
- 238000004321 preservation Methods 0.000 abstract description 7
- 239000006041 probiotic Substances 0.000 abstract description 7
- 235000018291 probiotics Nutrition 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 4
- 238000009629 microbiological culture Methods 0.000 abstract description 4
- 229940099352 cholate Drugs 0.000 abstract description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract description 2
- 235000013376 functional food Nutrition 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 33
- 238000012360 testing method Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 241000282898 Sus scrofa Species 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 210000000941 bile Anatomy 0.000 description 12
- 230000001954 sterilising effect Effects 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 11
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 238000012797 qualification Methods 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 239000002054 inoculum Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 208000019637 Infantile Diarrhea Diseases 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 239000003833 bile salt Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 238000003794 Gram staining Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 238000010241 blood sampling Methods 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000006916 nutrient agar Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 4
- 238000011047 acute toxicity test Methods 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940054441 o-phthalaldehyde Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010093965 Polymyxin B Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000000923 atherogenic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 238000011056 performance test Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 3
- 229920000024 polymyxin B Polymers 0.000 description 3
- 229960005266 polymyxin b Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003239 susceptibility assay Methods 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960003311 ampicillin trihydrate Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical class NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000001357 Cystobacterineae bacterium Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000786103 Steatomys pratensis Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002856 computational phylogenetic analysis Methods 0.000 description 1
- -1 contains two sources Chemical compound 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- XFIKMPRBSORKQP-JATHGWPISA-M lithium;9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3-[(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoate Chemical class [Li+].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 XFIKMPRBSORKQP-JATHGWPISA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 description 1
- 229950006796 spiramycin ii Drugs 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 108010046845 tryptones Proteins 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Provided is fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll. The fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll is Bifidobacterium animalis subsp.Lactis, the pure culture of the fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll is preserved at the China General Micro-biological Culture Collection Center (CGMCC), China Microbial Culture Preservation Management Committee, the address is Institute of Microbiology, Institution No.3 China Academy of Science, Western Beichen Road No.1 in Chaoyang District of Beijing in China, the postal code is 100101, the preservation number is CGMCC NO.10224, and the Bifidobacterium animalis subsp.Lactis BZll is called for short. The Bifidobacterium animalis subsp.Lactis BZll is high in cholesterol-assimilating capacity, acid resistance and cholate resistance, good in oxygen resisting performance, has probiotic property and can serve as probiotics to be added into a fermentative milk product to produce a functional food, bifidobacterium culture resources are enriched, and development of bifidobacterium health-care products is facilitated.
Description
Technical field
The present invention relates to microorganism, particularly decreasing cholesterol, oxytolerant bifidus bacillus.
Background technology
Cholesterol is extensively present in animal tissue cell, and be one of important component forming cell, in human body, play important physiological action, it transforms formation steroid hormone in vivo, is the precursor substance of synthesis of vitamin d and bile acide.Body inner cholesterol mainly contains two sources, and one is food, and two is endogenous synthesis.Some people is due to unreasonable dietary, and blood cholesterol level exceedes normal index; And body inner cholesterol too high levels can cause the cardiovascular and cerebrovascular diseases such as atherosclerosis, coronary heart disease, serious threat is to human health.It is reported, whole world cardiovascular and cerebrovascular diseases causes the number of human death to account for 29% of total death toll, predict according to the World Health Organization, to the year two thousand thirty, cardiovascular and cerebrovascular diseases will be the major cause causing human death, and cholesterol in serum too high be the important factor causing the cardiovascular and cerebrovascular diseases such as coronary heart disease, arteriosclerosis, cerebral apoplexy.Studies have found that compared with the people having normal lipid, the risk that the people of hypercholesterolemia suffers from a heart complaint is 3 times of its normal people.Therefore, be the feasible research direction of a kind of actual effect by reducing that serum cholesterol level prevents and treats cardiovascular and cerebrovascular diseases, have potential using value and wide be the market space.
For reducing body inner cholesterol, except by except reasonable diet, using biotransformation method, particularly using probiotic bacterium to carry out to cholesterol the trend that direct degraded has become research.Bifidus bacillus as the class probiotic bacterium in human intestinal, its prebiotic effect have maintain intestinal flora balance, reduce serum cholesterol, the prebiotic effect such as antitumor.And Guizhou Xiang Zhu Shi Guizhou Province characteristic resources, belong to miniature pig, its inheritance stability, organ structure is similar to human body with function.Therefore, the bifidus bacillus screened from fragrant pig is easy to be accepted by human body and utilize.
In current Chinese patent database, the patent application relating to bifidus bacillus is a lot, but relates to No. ZL2009100965117 " a kind of oxygen-resistant bifidobacteria " of the patent application Jin You Zhejiang University application of oxytolerant bifidus bacillus and No. ZL2011100894937 " a kind of oxygen-resistant acid-resistant Bifidobacterium longum " of University Of Science and Technology Of Tianjin's application.These two bifidus bacilluss can decreasing cholesterol unknown.Up to now, there is no the application part relating to decreasing cholesterol, oxytolerant animal bifidobacteria.
Summary of the invention
The present invention aims to provide a strain fragrant pig source property decreasing cholesterol, oxytolerant bifidus bacillus, make it likely to utilize as the further deep development of probiotic bacterium, add in cultured milk prod and become functional foodstuff, to reduce human cholesterol content, promote human health.
The fragrant pig source property decreasing cholesterol that contriver provides, oxytolerant bifidus bacillus, this bacterial strain is bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.Lactis), the pure growth of this bacterial strain is preserved in China Committee for Culture Collection of Microorganisms's common micro-organisms center (CGMCC) on December 18th, 2014, this centre address is: No. 3, No. 1, North Star West Road, Chaoyang District, city of BeiJing, China institute, Institute of Microorganism, Academia Sinica, postcode: 100101; Deposit number is CGMCC NO.10224, referred to as bifidobacterium animalis subspecies BZ11.This bacterial strain is that screening and separation and purification obtain from the enteron aisle Dissolve things inside of Guizhou characteristic resources Mini-musk swine.
The morphological specificity of above-mentioned bifidobacterium animalis subspecies BZ11 and physiological and biochemical property bacterium are all close to genus bifidobacterium, the 16S rRNA sequence homology of its 16S rRNA gene order and bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.Lactis) is 100%, according to the categorised regulation of genus bifidobacterium in " uncle Jie Shi systematic bacteriology handbook ", bifidobacterium animalis subspecies BZ11 belongs to actinomycetes door (Actinobacteria), Actinomycetes (Actinobacteria), actinomycetes subclass (Actinobacteridae), bifidus bacillus order (Bifidoacteriales), bifidobacterium family (Bifidobacteriaceae), genus bifidobacterium (Bifidobacterium), bifidobacterium animalis subspecies (Bifidobacteriumanimalis subsp.Lactis).
The security of above-mentioned animal bifidobacteria BZ11 is as follows: this bacterial strain to penicillin G, piperacillin, amoxycilline Trihydrate bp/clavulanic acid, vancomycin, cefotaxime, Kefzol, Azythromycin, Rifampin, furadantin 9 class antibiotic sensitive, to Ciprofloxacin, Liu Suanyan NEOMYCIN SULPHATE, trimethoprim-sulfamethoxazole, Ofloxacine USP 23, norfloxicin and PXB totally 6 class antibiotics resistances.In penicillin medicine, this bacterial strain is to ampicillin sensitive; In cephalo element class medicine, this bacterial strain is responsive to cefoperazone; In Macrocyclolactone lactone kind medicine, bacterial strain BZ11 is to the mould sensitivity of acetyl spiral; In quinolones, this bacterial strain is responsive to woods mycin.And by gavage mouse experiment, show that bifidobacterium animalis subspecies BZ11 bacterial strain is without acute toxicity, and therefore can the security of tentative confirmation BZ11 bacterial strain, the further deep development of probiotic bacterium can be considered as and utilize.And demonstrate decreasing cholesterol effect in its body further by gavage mouse experiment.
The bacterial strain that contriver provides from the characteristic resources Mini-musk swine enteron aisle Dissolve things inside of Guizhou, is separated also preliminary screening go out to have the bifidus bacillus of decreasing cholesterol ability, and to the bacterial strain of gained with decreasing cholesterol rate, acid and bile salt tolerance is that index carries out further multiple sieve by property, sift out again a strain removal rate of cholesterol high and acidproof by property, the bifidobacterium strains that bile tolerance is subject to property all good, then oxytolerant performance test is carried out, safety evaluation experiment and gavage mouse experiment, afterwards by carrying out morphology to this bacterial strain, physiological and biochemical test qualification and 16S rRNA Sequence Identification, finally identifying this bacterial strain is bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.Lactis).
In order to verify bacterial strain of the present invention, inventors performed following experiment:
(1) collection of sample and separation and purification
From multiple positions sampling of Guizhou Province's characteristic resources Mini-musk swine, comprise in small intestine, large intestine and fresh Mini-musk swine ight soil, number and record, and take back laboratory treatment rapidly.The fresh sample of getting 10g puts into the stroke-physiological saline solution that 90mL is housed, and after manually shaking up, in clean bench, draw 100 μ l mixed solutions with liquid-transfering gun coat on the MRS flat board containing Li-Mupirocin, (anaerobic environment is N to be placed in anaerobic culture box
2: CO
2: H
2=90: 5: 5), in, cultivate 48h for 37 DEG C, then picking list colony inoculation is on the PTYG flat board containing X-gal, puts into 37 DEG C, 20%CO
2cultivate two days in the CO2gas incubator of concentration, observe colony colour, form carry out gramstaining, microscopy, record strain morphology feature.Gone down to posterity by doubtful bifidobacterium strains purifying on PTYG flat board after 4 times, glycerol stocks is in the very low temperature refrigerator-freezer of-80 DEG C.
Above-mentioned MRS nutrient agar composition is: peptone 10g, extractum carnis 10g, yeast powder 5g, glucose 20g, tween 80 1mL, K
2hPO
42g, sodium-acetate 5g, dibasic ammonium citrate 2g, MgSO
47H
2o 0.58g, MnSO
44H
2o 0.25g, agar 20g; Method for making is by each composition heating for dissolving in 1000mL distilled water, adjust pH to 6.5, and 121 DEG C of sterilizing 15min are for subsequent use.
Above-mentioned containing in the MRS of Li-Mupirocin, 100mLMRS nutrient agar contains the mupirocin lithium salts (Li-Mupirocin) of 5mg.
Above-mentioned PTYG liquid culture based component is: Tryptones 5g, soy peptone 5g, yeast powder 10g, glucose 10g, tween 80 1mL, salts solution 40mL; Method for making is by each composition heating for dissolving in 1000mL distilled water, adjust pH to 6.5, and 121 DEG C of sterilizing 15min are for subsequent use.
Salts solution composition in above-mentioned substratum is: anhydrous CaCl
20.2g, K
2hPO
41.0g, KH
2pO
41.0g, MgSO
47H
2o 0.48g, Na
2cO
310g, NaCl 2g; Method for making is by CaCl
2and MgSO47H
2o is blended in until dissolve in 300mL distilled water, and add 500mL water, stirring slowly adds other salts simultaneously, until dissolve; Add 200mL distilled water again, after mixing, be stored in 4 DEG C, for subsequent use.
Above-mentioned PTYG nutrient agar method for making is: in the liquid nutrient medium of every 1000mL, add 20g agar powder, heated and boiled, and pour plate after 121 DEG C of sterilizing 15min is for subsequent use.
Above-mentioned PTYG (PTYG-X) the substratum method for making containing X-gal is: in the improvement PTYG substratum of every 1000mL, add X-gal 40mg, due to X-gal non-refractory, direct sterilized water weaker concn is 20mg/mL, each PTYG flat board coating 40 μ L, for subsequent use.
(2) mensuration of removal rate of cholesterol
O-phthalaldehyde method (OPA) is adopted to survey its removal rate of cholesterol the bacterial strain of primary dcreening operation gained.
(3) preparation of bacteria suspension to be measured
By the bacterial strain activation be deposited in the very low temperature refrigerator-freezer of-80 DEG C, after line purifying 3 times, be inoculated in PTYG liquid nutrient medium and carry out enrichment culture, then that bacteria suspension is centrifugal, collect bacterium mud, bacterial concentration is adjusted to 10
8cFU/mL, bacterium suspension band is used for external tolerance test.
(4) sour tolerance test
Bacteria suspension to be measured is inoculated in the sterilizing PTYG liquid nutrient medium of pH3.0 and pH7.0 respectively by 5% (volume ratio) inoculum size, leaves standstill 2h at mixing latter 37 DEG C, carry out plate count.
(5) Bile salt resistance experiment
Bacteria suspension to be measured is inoculated in the sterilizing PTYG liquid nutrient medium of interpolation 0.3% (mass/volume) bovine bile respectively by the inoculum size of 5% (volume ratio) and does not contain in the sterilizing PTYG liquid culture of bovine bile, 37 DEG C, cultivate in CO2gas incubator, carry out live bacterial count respectively at 0h and 24h.
(6) oxytolerant performance test
By the inoculation through acid resistance and Bile salt resistance in PTYG substratum respectively at standard incubator and 20%CO
2cO2gas incubator in cultivate 24h after, carry out plate count.Go to contrast to judge its oxygen resistence to both growths.
By the primary dcreening operation experiment of above-mentioned sampling, separation and purification and with the decreasing cholesterol rate of bacterial strain, tolerance is that index carries out multiple sieve, finally obtains a strain bacterial strain BZ11, its decreasing cholesterol rate is high, reach 38.52%, and acidproof property and the bile tolerance of being subject to is subject to property good, and has better tolerance to oxygen.
(7) the safety evaluation experiment of bacterial strain
A, drug sensitivity assay
By the activation of BZ11 bacterial strain and in PTYG nutrient agar after purifying 3 generation, liquid PTYG substratum enrichment culture, then by bacterium liquid at 5000r/min, centrifugal 10min under 4 DEG C of conditions, after collecting the washing of bacterium mud, is configured to 10 with PBS damping fluid
8the bacteria suspension of CFU/mL.Then choose 8 class, 19 kinds of susceptibility analoidses, adopt K-B drug sensitive test paper agar diffusion method to carry out drug sensitivity assay.
B, acute toxicity test
After BZ11 bacterial strain is activated, separation and purification three times, inoculating strain cultivates 48h in CO2gas incubator in the liquid nutrient medium of PTYG, by bacterium liquid with 5000r/min, centrifugal 10min under 4 DEG C of conditions, collect bacterium mud, then wash with sterile phosphate buffer PBS newly formed suspension of once laying equal stress on, bacterial concentration is adjusted to 3 × 10
10cFU/mL.Then acute toxicity test is carried out according to toxicological evaluation of food safety procedure and method.
(8) experiment in vivo of decreasing cholesterol, oxytolerant bifidus bacillus
Purifying 3 times after test strains BZ11 and control strain Infantile diarrhea thaw and activate, be inoculated in PTYG liquid nutrient medium with the inoculum size of 5% (volume ratio) respectively, cultivate 24h in the CO2gas incubator of 37 DEG C after, with centrifugal 10min under 5000r/min, 4 DEG C of conditions, collect bacterium mud.Carry out 10 times of gradient dilutions with sterilizing PBS damping fluid again, get 0.1mL and be coated with on PTYG agar plate, carry out enumeration after 37 DEG C of cultivation 36 ~ 48h, according to plate count result, respectively BZ11 and Infantile diarrhea are adjusted to bacteria suspension to 3.0 × 10
9cFU/mL.Then carry out mouse stomach experiment, took a blood sample the 10th, 20 day time, survey total cholesterol level in its serum, content of triglyceride, high density lipoprotein cholesterol content, low density lipoprotein cholesterol content, and calculate its atherogenic index.For preventing bifidus bacillus death from affecting result, fresh configuration every day bacterium liquid, timing in the morning is filled with and is fed and placement feed.
(9) qualification of bacterial strain
The bacterial strain of gained is carried out to the qualification of Physiology and biochemistry qualification and kind, understand its physiological and biochemical property, to effectively applying document, instructing further investigation and application to play an important role.Therefore, bacterial strain BZ11 of the present invention is carried out to the qualification of bio-chemical characteristics qualification and 16S rRNA sequence.
Morphological specificity: by inoculation on PTYG flat board, cultivate 48h for 37 DEG C, its colonial morphology is that bacterium colony is less, smooth, dome, neat in edge, white or oyster white are opaque and quality soft, and PTYG-X flat board then presents navy blue bacterium colony.Its bacterium colony of picking carries out gramstaining, and its gramstaining is positive, and to observe its cellular form be under an optical microscope polymorphic shaft-like, meets bifidobacterium cells morphological specificity.Its bio-chemical characteristics the results are shown in Table 1.
Table 1 cellular form and Physicochemical test result
Note :+: positive ,-: negative
According to above cellular form with Physicochemical test result, bacterial strain BZ11 feature meets the feature of genus bifidobacterium, and preliminary evaluation belongs to genus bifidobacterium.
Bacterial strain of the present invention is by China General Microbiological culture presevation administrative center (China General Microbiological Culture Col lection Center, CGMCC) 16S rRNA Sequence Identification is carried out, measured 16S rRNA gene order is logged in https://blast.ncbi.nlm.nih.gov/Blast.cgi website, by online BLAST (Basic Local Al ignment Search Tool), search 100 gene fragments higher with this sequence homology altogether, and the 16S rRNA sequence homology of the 16S rRNA gene order of this bacterial strain and bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.Lactis) reaches 100%, choose the 20 strain bacterium that homology is higher, application MEGA5.0 analysis software constructing system evolutionary tree.Mapping display, in animal bifidobacteria BZ11 bacterial strain and Genbank, Bifidobacterium animalis subsp.lactis AD011strain AD011 and Bifidobacterium animalis subsp.lactis strain YIT 4121 liang of strain bifidobacterium animalis subspecies belong in a minimum branch, show that the sibship between them is nearest.
Therefore, according to its morphological specificity, Physicochemical test result and the phylogenetic tree analysis constructed by 16S rRNA gene order, according to the categorised regulation of genus bifidobacterium in " uncle Jie Shi systematic bacteriology handbook ", bifidobacterium animalis subspecies BZ11 bacterial strain belongs to actinomycetes door (Actinobacteria), Actinomycetes (Actinobacteria), actinomycetes subclass (Actinobacteridae), bifidus bacillus order (Bifidoacteriales), bifidobacterium family (Bifidobacteriaceae), genus bifidobacterium (Bifidobacterium), bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.Lactis).
Fragrant pig source property bifidobacterium animalis subspecies BZ11 (Bifidobacterium animalis subsp.Lactis) of the present invention, not only decreasing cholesterol ability high, acidproof by property, bile tolerance by property, oxytolerant is functional and have probiotic properties, and can add in cultured milk prod as probiotic bacterium and become functional foodstuff, thus enriched bifidobacterium species resource, to the exploitation of bifidus bacillus healthcare product, there is positive effect.
The invention will be further described in conjunction with the embodiments with reference to the accompanying drawings.
Accompanying drawing explanation
Fig. 1 is that the 16S rRNA sequential system of bacterial strain BZ11 of the present invention and relevant bacteria species grows evolutionary tree, Fig. 2 is the colonial morphology figure of bacterial strain BZ11, Fig. 3 is the gramstaining schematic diagram of bacterial strain BZ11, Fig. 4 is the canonical plotting of Determination of Cholesterol Content, Fig. 5 is that bacterial strain BZ11 is to green grass or young crops-penicillin G, ammonia-Ampicillin Trihydrate, oxygen-piperacillin, amp-amoxycilline Trihydrate bp/clavulanic acid antibiotic susceptibility, Fig. 6 be bacterial strain BZ11 to must-cefoperazone, oxime-cefotaxime, V-Cephazolin, Ah-Azythromycin antibiotic susceptibility, Fig. 7 is that bacterial strain BZ11 is to second-acetyl spiral shell mycin, newly-Liu Suanyan NEOMYCIN SULPHATE, multiple-trimethoprim-sulfamethoxazole, ten thousand-vancomycin antibiotic drug susceptibility, Fig. 8 is that bacterial strain BZ11 is to ring-Ciprofloxacin, piperazine-Ofloxacine USP 23, fluoro-norfloxicin, gram-clindamycin antibiotic susceptibility, Fig. 9 is that bacterial strain BZ11 is to profit-Rifampin, furan-furadantin, many-PXB antibiotic susceptibility.
Embodiment
Embodiment 1: screening and separation screening obtain animal bifidobacteria BZ11 from the enteron aisle Dissolve things inside of Guizhou Province's characteristic resources Mini-musk swine:
(1) collection of sample:
Mini-musk swine multiple positions sampling that pig is less than 2 months age is got from the ecological park of Guiyang City, Guizhou Province, comprise small intestine, large intestine and fresh Mini-musk swine ight soil, with sterilized tweezers, fresh Mini-musk swine sample is positioned in sterile seal bag, put into the refrigeration certainly that ice bag is housed after numbering and mutually, in 1h, take back laboratory treatment;
(2) separation of bifidus bacillus and purifying
The fresh sample of 10g is put into the sterile purified water (including granulated glass sphere) that 90mL is housed, after manually shaking up, carry out gradient dilution.In Bechtop, get in MRS (MUP-MRS) plate culture medium that its sample diluting liquid 0.1mL joins containing Li-Mupirocin and be coated with, (anaerobic environment is N to put into anaerobic culture box
2: CO
2: H
2=90: 5: 5), cultivate two days for 37 DEG C, then picking list colony inoculation is on PTYG (PTYG-X) flat board containing X-gal, puts into 37 DEG C, 20%CO
22d is cultivated in the CO2gas incubator of concentration.Attention: from diluted sample to coating, requires that the plate exposure aerial time is no more than 15min.
(3) colonial morphology and cell morphological characteristic are observed
In sample preparation and after cultivating, observe and record colonial morphology, color, and carrying out gramstaining, microscopy is observed and record.Select the single bacterium colony that bacterium colony on MUP-MRS flat board is less, smooth, dome, neat in edge, white or oyster white are opaque, quality is soft, and on PTYG-X flat board, present navy blue bacterium colony, purifying goes down to posterity after four times, obtains purifying bacterial strain, numbers and records the form of bacterium colony.
(4) preservation of bacterial strain
By the inoculation that obtains in PTYG liquid nutrient medium, after cultivating 48h at 37 DEG C in CO2gas incubator, get 2mL bacterium liquid and 3mL50% glycerine is mixed in the sterilized clean centrifuge tube of 10mL, finally make its glycerol concentration reach 30%, be positioned in the very low temperature refrigerator-freezer of-80 DEG C and carry out freezing and preserving.
Through first round primary dcreening operation, with colonial morphology and strain morphology for index, preliminary screening goes out the doubtful bifidobacterium strains of more than 70 strain, and glycerol stocks is in the very low temperature refrigerator-freezer of-80 DEG C.
(5) mensuration of decreasing cholesterol rate: adopt o-phthalaldehyde(OPA) (OPA) method to survey its decreasing cholesterol rate, its concrete grammar is as follows:
A, o-phthalaldehyde method (OPA) Specification Curve of Increasing
Accurate absorption cholesterol standardized solution is each 0.02,0.05,0.10,0.12,0.15,0.20mL in clean tube, then adds dehydrated alcohol and makes its volume be 1mL, then in each test tube, add OPA reagent 4mL, room temperature places 10min.Slowly add the 4mL vitriol oil wherein again, to shake 20s with vibrator immediately, fully under room temperature dark condition, place 10min after mixing.Blank replaces cholesterol storing solution with 1mL dehydrated alcohol, finally survey its light absorption value at 550nm place, take cholesterol concentration as X-coordinate, absorbance is that ordinate zou does typical curve as Fig. 1, calculating its equation of linear regression is y=4.9264x-0.0130, coefficient R
2be 0.9992.
The mensuration of b, bifidus bacillus cholesterol
The bacterial strain fast fetching of preservation at-80 DEG C is gone out activation, and after the flat lining out purifying of PTYG 3 times, is inoculated into after carrying out enrichment culture 48h under the same terms in liquid PTYG substratum, with 5000r/min, centrifugal 10min under 4 DEG C of conditions, collects thalline.Then with PBS buffered soln dilution thalline, bacterium liquid to be measured is adjusted to 3 × 10
8being inoculated in cholesterol level by 10% (v/v) inoculum size after CFU/mL is in the cholesterol PTYG substratum of 0.1mg/mL, anaerobic environment, cultivates 48h for 37 DEG C.Bacterium liquid is with 10000r/min, and centrifugal 20min under 4 DEG C of conditions, retains supernatant liquid as liquid to be measured, wash tears bacterium mud twice with PBS buffered soln simultaneously, washing lotion is incorporated to supernatant liquid to be measured, for measuring cholesterol level, using nonvaccinated cholesterol PTYG substratum as blank group.Then o-phthalaldehyde(OPA) (OPA) method is adopted to survey its bifidus bacillus decreasing cholesterol rate.
Decreasing cholesterol rate S calculates as follows:
S＝(1-A/B)×100％
Note: S-decreasing cholesterol rate, %
Cholesterol concentration in A-fermented supernatant fluid to be measured, mg/mL
Cholesterol concentration in B-nonvaccinated cholesterol PTYG substratum, mg/mL
Through first time multiple sieve, go out 7 strain decreasing cholesterol rates higher than the bacterial strain of 30% with decreasing cholesterol rate for index screening, carry out next step multiple sieve.
(6) preparation of suspension to be measured
The bacterial strain fast fetching of preservation at-80 DEG C is gone out activation, and the flat lining out purifying of PTYG 3 times, be inoculated into after carrying out enrichment culture 48h under the same terms in liquid PTYG substratum, by bacterium liquid at 5000r/min, centrifugal 10min under 4 DEG C of conditions, collect bacterium mud, then wash tears once seriously ill newly formed suspension with sterile phosphate buffer salt PBS, bacterial concentration is adjusted to 10
8cFU/mL, suspension band is used for external tolerance test.
(7) sour tolerance test
Bacteria suspension to be measured is inoculated in the sterilizing PTYG liquid nutrient medium of pH3.0 and pH7.0 by 5% (volume ratio) inoculum size respectively, 2h is left standstill in 37 DEG C of constant temperature after mixing, getting 1mL, to join containing 9mL massfraction be in the test tube of 0.84% stroke-physiological saline solution, mix with quick vortex mixer, continue 10 times and successively decrease and be diluted to suitable gradient.Respectively get 0.1mL and coat dull and stereotyped upper 37 DEG C of PTYG, cultivate 48h in CO2gas incubator, carry out live bacterial count, each flat board does 3 parallel repetitions.Survival rate N is gone out according to following formulae discovery.
N＝N
0/N
1×100％
In formula, N-bacterial strain acid resistance survival rate
N
0-pH3.0PTYG cultivation 2h deposits viable count
N
1-pH3.0PTYG cultivation 2h deposits viable count
(8) Bile salt resistance experiment
By bacteria suspension to be measured by the inoculum size of 5% (volume ratio) be inoculated in respectively interpolation 0.3% ratio of volume (quality with) bovine bile sterilizing PTYG liquid nutrient medium and not containing in the sterilizing PTYG liquid culture of bovine bile, cultivate in 37 DEG C of CO2gas incubator, carry out live bacterial count respectively at 0h and 24h.Each flat board does 3 parallel repetitions.
(9) oxytolerant performance test
By the inoculation through acid resistance and Bile salt resistance in PTYG substratum respectively at standard incubator and 20%CO
2cO2gas incubator in cultivate 24h after, carry out plate count.Its oxytolerant performance Y is evaluated according to following formula.
Y＝N
3/N
2×100％
In formula, the heat resistance survival rate of Y-bacterial strain
N
3the viable count after 24h is cultivated in-standard incubator
N
2-20%CO
2cO2gas incubator in cultivate the viable count after 24h
Result shows, cultivating the viable count after 24h in standard incubator is CO
2in incubator 12.4%, shows good oxygen resistence, and the growth performance of bacterial strain is good.
Through the multiple sieve of second time, with acid and bile salt tolerance by property for index carries out multiple sieve, the strain bacterial strain BZ11 decreasing cholesterol ability that filters out high and acidproof by property, bile tolerance by the good bacterial strain of property, its decreasing cholesterol rate reaches 38.52%, survival rate under pH value 3.0 condition is to 98.65%, in the PTYG substratum containing 0.3% cholate, its survival rate is to more than 90%, and its oxytolerant performance is good.
(10) the safety evaluation experiment of bacterial strain
A, drug sensitivity test
The bacterial strain fast fetching of preservation at-80 DEG C is gone out activation, and after the flat lining out purifying of PTYG 3 times, be inoculated into after carrying out enrichment culture 48h under the same terms in liquid PTYG substratum, by bacterium liquid at 5000r/min, centrifugal 10min under 4 DEG C of conditions, after collecting the washing of bacterium mud, be configured to 10 with PBS damping fluid
8the bacteria suspension of CFU/mL.Then K-B drug sensitive test paper agar diffusion method is adopted to carry out drug sensitivity test.
The PTYG-F nutrient agar got for examination bacterium liquid 0.5mL and 10mL about 50 DEG C mixes rapidly, pours in the sterilizing flat board of ready 10mL agar shop fixtures.After substratum cooled and solidified, be placed with standard drug sensitive test paper, put into the CO2gas incubator of 37 DEG C, about 20h measures afterwards and records the diameter of inhibition zone.
The pharmacological action that this experimental basis is different, have selected 8 large classes, 19 kinds of antibacterials, penicillins respectively: comprise penicillin G (penicillin), Ampicillin Trihydrate (ampicillin), the mixture of piperacillin (piperacillin) and beta-lactam inhibitor: amoxycilline Trihydrate bp/clavulanic acid (amoxicillin/clavulanic), glycopeptide class: comprise vancomycin (vancomycin) and Ciprofloxacin (ciprofloxacin), cephalosporin: comprise cefotaxime (cefotaxime), Kefzol (cefoazolin) and cefoperazone (cefoperazon), Macrolide: comprise Azythromycin (azithromycin) and acetyl spiral mould (acetylspiramycin), aminoglycoside: Liu Suanyan NEOMYCIN SULPHATE (neomycin), sulfamido: trimethoprim-sulfamethoxazole (sulfomethorxazole), quinolones, comprise Ofloxacine USP 23 (ofloaxacin), norfloxicin (norfloxacin) and clindamycin (clindamycin) and other classes: comprise Rifampin (rifampin), furadantin (nitrofurantoin) and PXB (polymyxin B), drug sensitivity assay has been carried out to test strains, according to World Health Organization's regulation in 1977, during test gram-positive microorganism, need with Quality Control bacterium streptococcus aureus (Staphylococcus aureus) ATCC25923 bacterial strain as reference culture reference, result judges the NCCLS standard provided with reference to WHO.
B, acute toxicity test
After BZ11 bacterial strain is activated, separation and purification three times, inoculating strain cultivates 48h in CO2gas incubator in the liquid nutrient medium of PTYG, by bacterium liquid with 5000r/min, centrifugal 10min under 4 DEG C of conditions, collect bacterium mud, then wash with sterile phosphate buffer PBS newly formed suspension of once laying equal stress on, bacterial concentration is adjusted to 3 × 10
10cFU/mL.Then acute toxicity test is carried out according to toxicological evaluation of food safety procedure and method.
Select the male mouse 20 of the Kunming kind of healthy adult by body weight requirement, between mouse, weight differences is not remarkable.After adapting to Animal House environment (relative humidity: 50 ± 5%, temperature: 20 DEG C ~ 25 DEG C) 7d, mouse, by only weighing, is divided into 2 groups immediately, often organizes 10, i.e. experimental group and blank group.With BZ11 bacterium liquid, laboratory animal is contaminated, the mouse of fasting taboo water empty stomach 12h is carried out to the gavage volume of 0.4mL/20g body weight; Blank group mouse, with same dose gavage pure water.After mouse contamination, in one week, observe its general state, body weight change, toxicity symptom and death condition, within the 8th day, put to death mouse.Experiment is weighed to animal latter stage again, and carry out necrotomy to dead animal and the execution animal that expires, visual inspection general pathology changes situation.Experiment whole process and observed content do detailed record.
By carrying out safety experiment evaluation experimental to bacterial strain, result shows to screen the bacterial strain BZ11 that obtains without acute toxicity, confirms the security that bacterial strain BZ11 is preliminary, can be considered as the further deep development of probiotic bacterium and utilize.
(11) in vivo test of decreasing cholesterol, oxytolerant bifidus bacillus
Purifying 3 times after test strains BZ11 and control strain Infantile diarrhea thaw and activate, be inoculated in PTYG liquid nutrient medium with the inoculum size of 5% (volume ratio) respectively, 24h is cultivated in the CO2gas incubator of 37 DEG C, by bacterium liquid at 5000r/min, centrifugal 10min under 4 DEG C of conditions, collects bacterium mud.Carry out 10 times of gradient dilutions with sterilizing PBS damping fluid again, get 0.1mL and be coated with on PTYG agar plate, carry out enumeration after 37 DEG C of cultivation 36 ~ 48h, according to plate count result, respectively BZ11 bacterial strain and Infantile diarrhea are adjusted to as bacterial concentration is 3.0 × 10
9the bacteria suspension of CFU/mL.For preventing the death of bifidus bacillus from affecting result, fresh configuration every day bacterium liquid, timing in the morning is filled with and is fed and place feed.
The Kunming mouse 48 of healthy 4 weeks, male and female half and half, purchased from Guiyang Medical College.Mouse is divided into 4 groups at random, often organizes 12, male and female half and half.(relative humidity: 50 ± 5% in Animal House environment, temperature: 20 DEG C ~ 25 DEG C, 12h illumination every day, 12h is dark, and sanitation and hygiene environment is good) feed of freely drinking water, after normal diet normally raises 7d, weigh one by one, again be divided into 4 groups by mean body weight between each group without significant difference, often organize 12.Experimental result sees the following form:
Note: A group represents Normal group, B group represents hyperlipidemia model group, and C group represents that in Infantile diarrhea experiment, D group represents BZ11 experimental group.
Feed formulation and collocation method: basal feed is purchased from Guiyang Medical College, reference method, the formula of high lipid food is: lard 12%, cholesterol 1%, bovine bile 0.5%, basal feed 86.5%.Concrete feed making step is as follows: normal diet pulverizer is pulverized by (1), adds bovine bile etc. and mixes; (2) in pot, heat lard to boil, add cholesterol simultaneously and make it to dissolve; (3) join in the normal diet of mixing by the lard of liquid state, with glass stick mixing, more progressively add suitable quantity of water, carry out kneading and be shaped as cylindric feed, noting does not add water causes too softness not easy-formation too much.(4) be put in preservation in the refrigerator of 4 DEG C after making for subsequent use, be put into microwave-oven-heating during feeding about 5 seconds, take out.
Within the 10th, 20 day after gavage mouse experiment starts, carry out body weight determination one by one to experiment mice, whether the body weight of observing between group is variant.And often group random choose 10 mouse carry out blood specimen collection, having blood-sample withdrawal twice altogether in experimentation, is respectively once took a blood sample at the 10th, 20 day respectively, and respectively organizing mouse before each blood sampling needs fasting to prohibit water 12h.First time, Blood collection was the blood sampling of retroorbital venous clump, and second time is for plucking eyeball blood sampling, and blood sampling volume is 0.2mL/.After second time blood sampling, all mouse cervical dislocation are put to death.
By the blood sample collection of collection in the 2mL sterile centrifugation tube with antithrombotics, after 37 DEG C of water-bath 30min, the centrifugal 10min of 3000r/min, carefully gets upper serum.Reference reagent box operation instruction and employing microplate reader measure the content of total cholesterol (TC), triglyceride level (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) in serum.And calculate atherogenic index (Atherogenic index, AI), formula is as follows:
AI＝LDL-C/HDL-C
Compared with control strain Infantile diarrhea, the body weight impact of BZ11 bacterial strain on high fat mouse is larger, more can reduce total cholesterol (TC) content in mice serum, reduces the content of Triglycerides in Serum (TG), suppresses low density lipoprotein cholesterol (LDL-C) content in serum, improves high density lipoprotein cholesterol (HDL-C) content, reduce arteriosclerosis (AI) index.
(12) by above primary dcreening operation with sieve experiment again, finishing screen select bacterial strain BZ11 decreasing cholesterol ability high and acidproof by property, bile tolerance by property, oxytolerant bacterial strain of good performance, by carry out bio-chemical characteristics qualification and 16S rRNA gene order qualification.
Claims (3)
1. a strain fragrant pig source property decreasing cholesterol, oxytolerant bifidus bacillus BZ11, it is characterized in that this bacterial strain is bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.Lactis), the pure growth of this bacterial strain is preserved in China Committee for Culture Collection of Microorganisms's common micro-organisms center (CGMCC) on December 18th, 2014, this centre address is: No. 3, No. 1, North Star West Road, Chaoyang District, city of BeiJing, China institute, Institute of Microorganism, Academia Sinica, postcode: 100101; Deposit number is CGMCC NO.10224, referred to as bifidobacterium animalis subspecies BZ11.
2. fragrant pig source as claimed in claim 1 property decreasing cholesterol, oxytolerant bifidus bacillus BZ11, it is characterized in that the morphological specificity of described bifidobacterium animalis subspecies BZ11 and physiological and biochemical property bacterium are all close to genus bifidobacterium, its 16S rRNA gene order and bifidobacterium animalis subspecies (
bifidobacterium animalis subsp.
lactis ) 16S rRNA sequence homology be 100%, according to the categorised regulation of genus bifidobacterium in " uncle Jie Shi systematic bacteriology handbook ", bifidobacterium animalis subspecies BZ11 belongs to actinomycetes door (Actinobacteria), Actinomycetes (Actinobacteria), actinomycetes subclass (Actinobacteridae), bifidus bacillus order (Bifidoacteriales), bifidobacterium family (Bifidobacteriaceae), genus bifidobacterium (Bifidobacterium), bifidobacterium animalis subspecies (
bifidobacterium animalis subsp.
lactis ).
3. the fragrant pig source property decreasing cholesterol as described in one of claim 1 and 2, oxytolerant bifidus bacillus BZ11, it is characterized in that described bifidobacterium animalis subspecies BZ11 has security: this bacterial strain to penicillin G, piperacillin, amoxycilline Trihydrate bp/clavulanic acid, vancomycin, cefotaxime, Kefzol, Azythromycin, Rifampin, furadantin 9 class antibiotic sensitive, to Ciprofloxacin, Liu Suanyan NEOMYCIN SULPHATE, trimethoprim-sulfamethoxazole, Ofloxacine USP 23, norfloxicin and PXB totally 6 class antibiotics resistances; In penicillin medicine, this bacterial strain is to ampicillin sensitive; In cephalo element class medicine, this bacterial strain is responsive to cefoperazone; In Macrocyclolactone lactone kind medicine, this bacterial strain is to the mould sensitivity of acetyl spiral; In quinolones, this bacterial strain is responsive to woods mycin;
And by gavage mouse experiment, show that bifidobacterium animalis subspecies BZ11 bacterial strain is without acute toxicity, the therefore tentative confirmation security of this bacterial strain, and demonstrate decreasing cholesterol effect in its body further by gavage mouse experiment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510018144.4A CN104531590B (en) | 2015-01-14 | 2015-01-14 | One plant of fragrant pig source property norcholesterol, oxytolerant Bifidobacterium BZ11 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510018144.4A CN104531590B (en) | 2015-01-14 | 2015-01-14 | One plant of fragrant pig source property norcholesterol, oxytolerant Bifidobacterium BZ11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104531590A true CN104531590A (en) | 2015-04-22 |
| CN104531590B CN104531590B (en) | 2017-12-08 |
Family
ID=52847225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510018144.4A Active CN104531590B (en) | 2015-01-14 | 2015-01-14 | One plant of fragrant pig source property norcholesterol, oxytolerant Bifidobacterium BZ11 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104531590B (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104928215A (en) * | 2015-06-23 | 2015-09-23 | 贵州大学 | Fermentation medium cholesterol-lowering and oxygen-resistant animal bifidobacteria yoghurt subspecies BZ11 |
| CN106167775A (en) * | 2016-07-06 | 2016-11-30 | 贵州大学 | The fermentation process in high density of oxytolerant domestication bifidobacterium animalis subspecies BZ11 |
| CN108570429A (en) * | 2018-05-08 | 2018-09-25 | 西藏高原之宝牦牛乳业股份有限公司 | A kind of animal bifidobacteria and preparation method thereof |
| CN110577919A (en) * | 2019-10-14 | 2019-12-17 | 汉臣氏（沈阳）儿童制品有限公司 | heat-resistant bifidobacterium animalis subsp lactis separated from infant feces |
| CN110835614A (en) * | 2018-08-16 | 2020-02-25 | 葡萄王生技股份有限公司 | Bifidobacterium lactis GKK2, composition containing the same and use thereof for improving allergic asthma |
| CN111440750A (en) * | 2020-05-28 | 2020-07-24 | 汉臣氏（沈阳）儿童制品有限公司 | Bifidobacterium animalis subsp lactis with functions of relieving lactose intolerance and reducing triglyceride and application thereof |
| CN111484957A (en) * | 2019-12-11 | 2020-08-04 | 石家庄君乐宝乳业有限公司 | Bifidobacterium animalis subsp lactis i797, and separation and purification method and application thereof |
| CN111567809A (en) * | 2020-05-26 | 2020-08-25 | 奥克斯路株式会社 | Bifidobacterium animalis BZ11 composite microbial agent with functions of improving immunity and regulating intestinal tract |
| CN111826300A (en) * | 2019-03-29 | 2020-10-27 | 株式会社Gfc生命科学 | Bifidobacterium animalis subsp lactis GFC-B09 strain and cosmetic composition containing the same |
| CN113564078A (en) * | 2021-07-29 | 2021-10-29 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium lactis BLA80 for reducing cholesterol and application thereof |
| CN114574407A (en) * | 2022-05-06 | 2022-06-03 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis WKB99, and application and product thereof in preparation of product for improving metabolic syndrome |
| CN114606157A (en) * | 2022-03-01 | 2022-06-10 | 武汉工控工业技术研究院有限公司 | Bifidobacterium microbial preparation and application thereof in kefir wine preparation |
| CN114686393A (en) * | 2020-12-31 | 2022-07-01 | 杭州远大生物制药有限公司 | Bifidobacterium animalis subsp lactis and composition thereof |
| CN117305150A (en) * | 2023-07-10 | 2023-12-29 | 贵州大学 | Bifidobacterium animalis BLH1, direct vat set starter and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101257910A (en) * | 2005-09-08 | 2008-09-03 | 株式会社益力多本社 | Cholesterol absorption inhibitor |
| CN101503667A (en) * | 2009-03-05 | 2009-08-12 | 浙江大学 | Oxygen-resistant bifidobacteria |
| CN102191192A (en) * | 2010-12-21 | 2011-09-21 | 北京博锦元生物科技有限公司 | Animal Bifidobacterium and use method thereof |
| CN102206599A (en) * | 2011-04-11 | 2011-10-05 | 天津科技大学 | Oxygen-resistant acid-resistant Bifidobacterium longum |
| CN102488004A (en) * | 2011-12-01 | 2012-06-13 | 杭州娃哈哈集团有限公司 | Norcholesterol 0-fat fermented milk and preparation method thereof |
-
2015
- 2015-01-14 CN CN201510018144.4A patent/CN104531590B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101257910A (en) * | 2005-09-08 | 2008-09-03 | 株式会社益力多本社 | Cholesterol absorption inhibitor |
| CN101503667A (en) * | 2009-03-05 | 2009-08-12 | 浙江大学 | Oxygen-resistant bifidobacteria |
| CN102191192A (en) * | 2010-12-21 | 2011-09-21 | 北京博锦元生物科技有限公司 | Animal Bifidobacterium and use method thereof |
| CN102206599A (en) * | 2011-04-11 | 2011-10-05 | 天津科技大学 | Oxygen-resistant acid-resistant Bifidobacterium longum |
| CN102488004A (en) * | 2011-12-01 | 2012-06-13 | 杭州娃哈哈集团有限公司 | Norcholesterol 0-fat fermented milk and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| RUJIAO ZHANG等: "Screening of Cholesterol-lowering Bifidobacterium from Guizhou Xiang Pigs, and Evaluation of Its Tolerance to Oxygen, Acid, and Bile", 《KOREAN J. FOOD SCI. AN.》 * |
| 何腊平等: "降胆固醇双歧杆菌的研究进展", 《中国食品添加剂》 * |
| 杨琴等: "降胆固醇乳酸菌的筛选及对大鼠血脂的影响", 《食品科学》 * |
| 王猛等: "动物双歧杆菌乳亚种BZ11的耐氧驯化及降胆固醇性能的研究", 《食品与发酵工业》 * |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104928215A (en) * | 2015-06-23 | 2015-09-23 | 贵州大学 | Fermentation medium cholesterol-lowering and oxygen-resistant animal bifidobacteria yoghurt subspecies BZ11 |
| CN106167775A (en) * | 2016-07-06 | 2016-11-30 | 贵州大学 | The fermentation process in high density of oxytolerant domestication bifidobacterium animalis subspecies BZ11 |
| CN106167775B (en) * | 2016-07-06 | 2019-11-12 | 贵州大学 | The fermentation process in high density of oxytolerant domesticated animal Bifidobacterium lactis spp BZ11 |
| CN108570429A (en) * | 2018-05-08 | 2018-09-25 | 西藏高原之宝牦牛乳业股份有限公司 | A kind of animal bifidobacteria and preparation method thereof |
| CN110835614B (en) * | 2018-08-16 | 2023-08-25 | 葡萄王生技股份有限公司 | Bifidobacterium lactis GKK2, composition containing same and application of composition in improving allergic asthma |
| CN110835614A (en) * | 2018-08-16 | 2020-02-25 | 葡萄王生技股份有限公司 | Bifidobacterium lactis GKK2, composition containing the same and use thereof for improving allergic asthma |
| CN111826300A (en) * | 2019-03-29 | 2020-10-27 | 株式会社Gfc生命科学 | Bifidobacterium animalis subsp lactis GFC-B09 strain and cosmetic composition containing the same |
| CN111826300B (en) * | 2019-03-29 | 2023-11-28 | 株式会社洁肤洗生命科学 | Bifidobacterium animalis subspecies lactis GFC-B09 strain and cosmetic composition containing same |
| CN110577919A (en) * | 2019-10-14 | 2019-12-17 | 汉臣氏（沈阳）儿童制品有限公司 | heat-resistant bifidobacterium animalis subsp lactis separated from infant feces |
| CN110577919B (en) * | 2019-10-14 | 2022-12-23 | 江西仁仁健康产业有限公司 | Heat-resistant animal bifidobacterium lactis subspecies separated from infant feces |
| CN111484957A (en) * | 2019-12-11 | 2020-08-04 | 石家庄君乐宝乳业有限公司 | Bifidobacterium animalis subsp lactis i797, and separation and purification method and application thereof |
| CN111567809A (en) * | 2020-05-26 | 2020-08-25 | 奥克斯路株式会社 | Bifidobacterium animalis BZ11 composite microbial agent with functions of improving immunity and regulating intestinal tract |
| JP2021187826A (en) * | 2020-05-26 | 2021-12-13 | オクスロ株式会社 | Bifidobacterium animalis bz11 composite bacterial agent having function of improving immune strength and intestinal function adjustment |
| CN111440750A (en) * | 2020-05-28 | 2020-07-24 | 汉臣氏（沈阳）儿童制品有限公司 | Bifidobacterium animalis subsp lactis with functions of relieving lactose intolerance and reducing triglyceride and application thereof |
| CN114686393B (en) * | 2020-12-31 | 2023-09-05 | 杭州远大生物制药有限公司 | Bifidobacterium animalis subspecies lactis and composition thereof |
| CN114686393A (en) * | 2020-12-31 | 2022-07-01 | 杭州远大生物制药有限公司 | Bifidobacterium animalis subsp lactis and composition thereof |
| CN113564078A (en) * | 2021-07-29 | 2021-10-29 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium lactis BLA80 for reducing cholesterol and application thereof |
| CN113564078B (en) * | 2021-07-29 | 2023-10-20 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium lactis BLa80 for reducing cholesterol and application thereof |
| CN114606157B (en) * | 2022-03-01 | 2023-07-14 | 湖北省微工生物技术研究有限公司 | Bifidobacterium microbial preparation and application thereof in kefir preparation |
| CN114606157A (en) * | 2022-03-01 | 2022-06-10 | 武汉工控工业技术研究院有限公司 | Bifidobacterium microbial preparation and application thereof in kefir wine preparation |
| CN114574407B (en) * | 2022-05-06 | 2022-11-01 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis WKB99 and application thereof in preparation of product for improving metabolic syndrome and product |
| CN114574407A (en) * | 2022-05-06 | 2022-06-03 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis WKB99, and application and product thereof in preparation of product for improving metabolic syndrome |
| CN117305150A (en) * | 2023-07-10 | 2023-12-29 | 贵州大学 | Bifidobacterium animalis BLH1, direct vat set starter and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104531590B (en) | 2017-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104531590A (en) | Fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll | |
| CN104073455B (en) | One strain has the plant lactobacillus reducing cholesterol ability | |
| CN104560829B (en) | One plant of fragrant pig source property norcholesterol, oxytolerant Bifidobacterium BZ25 | |
| Orrhage et al. | Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil | |
| CN108004187A (en) | A kind of lactobacillus gasseri and its application for being used to prepare vagina antibacterial medicines | |
| JP2022524157A (en) | Composite Lactobacillus Composition and Its Uses in Vaginal Health in Women | |
| CN110373342A (en) | Lactobacillus reuteri and application thereof | |
| CN110106119B (en) | Lactobacillus rhamnosus M9 separated from breast milk and application thereof | |
| CN102191192A (en) | Animal Bifidobacterium and use method thereof | |
| CN107964520A (en) | A kind of compound lactobacillus probiotics and preparation method and application | |
| FI76373C (en) | Process for the preparation of a culture containing live cell assays of bifidobacteria and lactic acid bacteria | |
| CN106883995A (en) | Pediococcus acidilactici JQII-5 bacterial strains and application thereof | |
| CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
| CN106399154A (en) | Lactobacillus probiotics CGMCC NO. 12422 and application of lactobacillus probiotics in preparing lipid-lowering drug | |
| CN103446552B (en) | For the fermentation composition of prevention and therapy digestive system disease | |
| CN117143767B (en) | Breast milk-derived fermented lactobacillus mucilaginosus MSJK capable of regulating intestinal flora and application thereof | |
| RU2460778C1 (en) | Method for producing autoprobiotic of enterocuccus faecium being representative of indigenic host intestinal microflora | |
| CN114085789A (en) | Pediococcus pentosaceus MA.WTPQJ01 and application thereof | |
| CN112812999B (en) | Lactobacillus plantarum SLB01 with inhibition effect on enterobacter cloacae and derivative product and application thereof | |
| CN112195123B (en) | Lactobacillus plantarum and preparation and application thereof | |
| CN109456909A (en) | One plant has the Lactobacillus helveticus for reducing cholesterol ability | |
| Lochhead et al. | Aspects of antagonisms between micro-organisms in soil | |
| CN116491655B (en) | Application of probiotic prebiotic composition in preparation of food for improving intestinal probiotic colonization | |
| CN115704002B (en) | Clostridium butyricum CC02001 and application thereof | |
| CN108935949A (en) | A kind of feeding antibiotic alternative composite preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200327 Address after: Room 501, building 3, zone 3, No. 188, nansihuan West Road, Fengtai District, Beijing 100070 Patentee after: BEIJING ZHONGJING FENGCHUANG TECHNOLOGY Co.,Ltd. Address before: 550025 Guiyang Road, Huaxi District, Guizhou Province, Guizhou University (South Campus) Patentee before: Guizhou University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210108 Address after: 135099 No.1, building B, Laodong Jiayuan, Meihekou City, Tonghua City, Jilin Province Patentee after: Baizhi Health Technology (China) Co.,Ltd. Address before: Room 501, building 3, area 3, 188 South 4th Ring Road West, Fengtai District, Beijing 100070 Patentee before: BEIJING ZHONGJING FENGCHUANG TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211130 Address after: 135000 No. 3399, Nanhuan East Road, Meihekou City, Tonghua City, Jilin Province Patentee after: Naian Pharmaceutical (China) Co.,Ltd. Address before: 135099 No.1, building B, Laodong Jiayuan, Meihekou City, Tonghua City, Jilin Province Patentee before: Baizhi Health Technology (China) Co.,Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 135000 No. 3399, Nanhuan East Road, Meihekou City, Tonghua City, Jilin Province Patentee after: Naian Brewing (China) Co.,Ltd. Country or region after: China Address before: 135000 No. 3399, Nanhuan East Road, Meihekou City, Tonghua City, Jilin Province Patentee before: Naian Pharmaceutical (China) Co.,Ltd. Country or region before: China |
|
| CP03 | Change of name, title or address |